Breast-Specific Gamma Imaging Effective For All Breast Densities
Breast-specific gamma imaging detects breast cancer in both dense and nondense breast tissue.
Breast-specific gamma imaging (BSGI) is highly sensitive for detecting breast cancer in women with either dense or nondense breasts, according to a study published in the American Journal of Roentgenology.
Researchers from The George Washington University, in Washington, D.C., undertook a retrospective study of 341 women who had been diagnosed with breast cancer from January 2004 to August 2009 and who had undergone BSGI before surgical excision.
Women with predominantly fatty replaced (BI-RADS density 1) or scattered fibroglandular tissue (BI-RADS density 2) breasts were classified as nondense, and those with heterogeneously dense (BI-RADS density 3) or extremely dense tissue (BIRADS density 4) were classified as dense.
The results showed that overall sensitivity of BSGI for breast cancer detection was 95.4 percent. Positive BSGI examinations were present in 136 of 142 nondense breast cancers and 195 of 205 dense breast cancers, for sensitivities of 95.8 percent and 95.1 percent, respectively. There was no significant difference in BSGI breast cancer detection and parenchymal breast density.
“BSGI has high sensitivities for the detection of breast cancer in women with dense and nondense breasts and is an effective adjunct imaging modality in women with both dense and nondense breasts,” the authors concluded.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
